Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | isocitrate dehydrogenase 1 (NADP+), soluble | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0019 | 0 | 0.5 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.5926 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 1 | 1 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.0043 | 0.5926 | 0.5926 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5368 | 0.9059 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5368 | 0.5368 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5368 | 0.5368 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 1 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.5926 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5926 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.5926 | 1 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0019 | 0 | 0.5 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.5926 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5926 | 0.5 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0019 | 0 | 0.5 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0019 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5926 | 0.5 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5926 | 0.5 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.5623 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 0.7308 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.7783 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.3109 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.